Liechtenstein company Lysando AG and Korean company Amicogen Inc. have forged a strategic partnership. Lysando creates Artilysin®s, which are phage lysin-based antimicrobial proteins, and partnering with Amicogen will allow them to access the Asian market.
Cytophage Technologies, a Canadian phage biotech company, is about to start testing on animals a throat and nasal spray that would stop infection by COVID-19 and its variants. The idea is that the synthetic phage in their spray will stimulate the production of protective antibodies in the nose and throat.
Carol Zhou (Lawrence Livermore National Laboratory) and colleagues published a new paper in G3 Genes|Genomes|Genetics entitled MultiPhATE2: Code for functional annotation and comparison of phage genomes.
Danish Malik (Loughborough University) and colleagues published a new paper in Current Opinion in Biotechnology showing current approaches for manufacture, formulation, targeted delivery and controlled release of phage-based therapeutics.
Ryan Cook (University of Nottingham) and colleagues published a new paper in Microbiome showing how a hybrid assembly of an agricultural slurry virome revealed a diverse and stable community with the potential to alter the metabolism and virulence of veterinary pathogens.